Einstein (Sao Paulo, Brazil) · 2026
Cost of hematopoietic cell transplantation for hematologic malignancies from a transplant center in a developing country.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Silva Cinthya Corrêa da, Arcuri Leonardo Javier, Malheiro Daniel Tavares, Teich Vanessa Damazio, Hamerschlak Nelson
Аннотация
OBJECTIVE: Hematopoietic cell transplantation is a resource-intensive procedure influenced by several cost drivers. The primary objective of this study was to compare the costs of matched-sibling (MSD), unrelated (URD), and haploidentical (Haplo) donor transplants and to identify patient- and transplant-related factors associated with higher costs.
METHODS: This observational, retrospective cohort study compared the costs among human leucocyte antigen (HLA)-matched MSD, HLA-matched URD, and Haplo transplants. Patients with hematologic malignancies who underwent their first allogeneic hematopoietic cell transplantation were included. Median cost analyses were performed using a parametric lognormal survival model at 1 year. Patients who did not complete the follow-up were censored. The median follow-up was 53 months, and a total of 177 patients were included (54 MSD, 43 Haplo, and 80 URD).
RESULTS: Crude 1-year costs were US$83,753 for MSD, lower than those of URD (US$122,811) and Haplo (US$148,461) (p=0.01). In the 1-year cost model, Haplo (p=0.02) and URD (p=0.01) were associated with higher costs than MSD. In multivariable analysis, Haplo (p=0.008) and URD (p=0.004) remained independently associated with higher costs. Haplo costs were not significantly different from URD costs (p=0.84).
CONCLUSION: From a financial perspective, sibling transplantation remains the gold standard treatment.
METHODS: This observational, retrospective cohort study compared the costs among human leucocyte antigen (HLA)-matched MSD, HLA-matched URD, and Haplo transplants. Patients with hematologic malignancies who underwent their first allogeneic hematopoietic cell transplantation were included. Median cost analyses were performed using a parametric lognormal survival model at 1 year. Patients who did not complete the follow-up were censored. The median follow-up was 53 months, and a total of 177 patients were included (54 MSD, 43 Haplo, and 80 URD).
RESULTS: Crude 1-year costs were US$83,753 for MSD, lower than those of URD (US$122,811) and Haplo (US$148,461) (p=0.01). In the 1-year cost model, Haplo (p=0.02) and URD (p=0.01) were associated with higher costs than MSD. In multivariable analysis, Haplo (p=0.008) and URD (p=0.004) remained independently associated with higher costs. Haplo costs were not significantly different from URD costs (p=0.84).
CONCLUSION: From a financial perspective, sibling transplantation remains the gold standard treatment.